60 Degrees Pharmaceuticals (NASDAQ:SXTP) Trading Up 2.7%

60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP)’s stock price was up 2.7% on Friday . The stock traded as high as $0.24 and last traded at $0.24. Approximately 84,376 shares changed hands during trading, a decline of 71% from the average daily volume of 290,194 shares. The stock had previously closed at $0.23.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of 60 Degrees Pharmaceuticals in a research report on Wednesday, April 3rd.

60 Degrees Pharmaceuticals Stock Performance

The company has a 50-day simple moving average of $0.27 and a two-hundred day simple moving average of $0.55.

60 Degrees Pharmaceuticals (NASDAQ:SXTP) last posted its earnings results on Monday, April 1st. The company reported ($0.44) earnings per share for the quarter. The company had revenue of ($0.10) million during the quarter, compared to analyst estimates of $0.06 million. Sell-side analysts forecast that 60 Degrees Pharmaceuticals, Inc. will post -0.29 earnings per share for the current fiscal year.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.